MN Wealth Advisors LLC Has $450,000 Stock Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)

MN Wealth Advisors LLC lifted its position in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 215.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,628 shares of the biotechnology company's stock after acquiring an additional 12,728 shares during the period. MN Wealth Advisors LLC's holdings in Viking Therapeutics were worth $450,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. GSB Wealth Management LLC raised its position in shares of Viking Therapeutics by 12.2% in the 1st quarter. GSB Wealth Management LLC now owns 8,317 shares of the biotechnology company's stock valued at $201,000 after acquiring an additional 907 shares during the period. Compagnie Lombard Odier SCmA grew its stake in Viking Therapeutics by 286.0% in the first quarter. Compagnie Lombard Odier SCmA now owns 20,245 shares of the biotechnology company's stock valued at $489,000 after acquiring an additional 15,000 shares during the period. Wesbanco Bank Inc. grew its stake in Viking Therapeutics by 101.7% in the first quarter. Wesbanco Bank Inc. now owns 23,800 shares of the biotechnology company's stock valued at $575,000 after acquiring an additional 12,000 shares during the period. Principia Wealth Advisory LLC grew its stake in Viking Therapeutics by 10.5% in the first quarter. Principia Wealth Advisory LLC now owns 6,478 shares of the biotechnology company's stock valued at $150,000 after acquiring an additional 616 shares during the period. Finally, RFG Advisory LLC acquired a new position in Viking Therapeutics in the first quarter valued at about $958,000. 76.03% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

VKTX has been the subject of a number of research analyst reports. Cantor Fitzgerald raised Viking Therapeutics to a "strong-buy" rating in a research note on Tuesday, April 29th. Truist Financial reaffirmed a "buy" rating and issued a $75.00 price target (down previously from $95.00) on shares of Viking Therapeutics in a research note on Monday, April 28th. Morgan Stanley cut their price target on shares of Viking Therapeutics from $105.00 to $102.00 and set an "overweight" rating on the stock in a research note on Thursday, April 24th. HC Wainwright reaffirmed a "buy" rating and issued a $102.00 price target on shares of Viking Therapeutics in a research note on Thursday, April 24th. Finally, The Goldman Sachs Group assumed coverage on shares of Viking Therapeutics in a research note on Tuesday, April 8th. They issued a "neutral" rating and a $30.00 price target on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $87.15.

Insider Activity

In other news, Director Sarah Kathryn Rouan bought 1,240 shares of the stock in a transaction that occurred on Monday, March 31st. The shares were acquired at an average cost of $24.15 per share, for a total transaction of $29,946.00. Following the completion of the acquisition, the director now owns 1,240 shares in the company, valued at approximately $29,946. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 4.10% of the stock is owned by corporate insiders.

Viking Therapeutics Stock Down 2.0%

NASDAQ VKTX opened at $26.43 on Wednesday. Viking Therapeutics, Inc. has a 12-month low of $18.92 and a 12-month high of $81.73. The company has a market capitalization of $2.97 billion, a PE ratio of -22.98 and a beta of 0.65. The firm's 50 day moving average is $26.67 and its 200-day moving average is $31.65.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.10). During the same quarter in the prior year, the business posted ($0.26) EPS. The firm's revenue for the quarter was up .0% compared to the same quarter last year. As a group, sell-side analysts expect that Viking Therapeutics, Inc. will post -1.56 EPS for the current year.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.